134 related articles for article (PubMed ID: 23075336)
1. Post-marketing surveillance of levofloxacin 0.5% ophthalmic solution for external ocular infections.
Kanda Y; Kayama T; Okamoto S; Hashimoto M; Ishida C; Yanai T; Fukumoto M; Kunihiro E
Drugs R D; 2012 Dec; 12(4):177-85. PubMed ID: 23075336
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery.
Keating GM
Drugs; 2009 Jun; 69(9):1267-86. PubMed ID: 19537841
[TBL] [Abstract][Full Text] [Related]
3. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
4. [Clinical investigation of 0.3% levofloxacin eyedrops on the treatment of cases with acute bacterial conjunctivitis and bacterial keratitis].
Zhang M; Hu Y; Chen F
Yan Ke Xue Bao; 2000 Jun; 16(2):146-8. PubMed ID: 12579927
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group.
O'Brien TP; Maguire MG; Fink NE; Alfonso E; McDonnell P
Arch Ophthalmol; 1995 Oct; 113(10):1257-65. PubMed ID: 7575256
[TBL] [Abstract][Full Text] [Related]
6. [A review of safety and efficacy of levofloxacin 0.5% ophthalmic solution in the treatment of external ocular infections and in prophylaxis of postoperative endophthalmitis].
Lazicka-Gałecka M; Gałecki T; Szaflik JP
Klin Oczna; 2015; 117(2):123-9. PubMed ID: 26638552
[TBL] [Abstract][Full Text] [Related]
7. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study.
Schechter BA; Parekh JG; Trattler W
J Ocul Pharmacol Ther; 2015 Mar; 31(2):114-21. PubMed ID: 25409447
[TBL] [Abstract][Full Text] [Related]
8. Post-marketing surveillance of the safety of levofloxacin in Japan.
Yamaguchi H; Kawai H; Matsumoto T; Yokoyama H; Nakayasu T; Komiya M; Shimada J
Chemotherapy; 2007; 53(2):85-103. PubMed ID: 17259709
[TBL] [Abstract][Full Text] [Related]
9. Clinical and microbiological efficacy of levofloxacin administered three times a day for the treatment of bacterial conjunctivitis.
Szaflik J; Szaflik JP; Kaminska A;
Eur J Ophthalmol; 2009; 19(1):1-9. PubMed ID: 19123142
[TBL] [Abstract][Full Text] [Related]
10. Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
Walters T; Rinehart M; Krebs W; Holdbrook M
Cornea; 2010 Mar; 29(3):263-8. PubMed ID: 20098307
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients.
Lichtenstein SJ; Rinehart M;
J AAPOS; 2003 Oct; 7(5):317-24. PubMed ID: 14566313
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of levofloxacin 500 mg qd in the treatment of cervicitis and intrauterine infections caused by Chlamydia trachomatis].
Mikamo H; Yamagishi Y; Takahashi K; Izumi K; Hoshina S; Nakabe K; Fujiwara M; Yoshimura M; Ando Y; Kurashima M; Kinoshita C; Yoshioka M
Jpn J Antibiot; 2011 Aug; 64(4):217-29. PubMed ID: 22066346
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study.
Tanihara H; Kakuda T; Sano T; Kanno T; Imada R; Shingaki W; Gunji R
Adv Ther; 2019 Feb; 36(2):333-343. PubMed ID: 30610614
[TBL] [Abstract][Full Text] [Related]
14. Topical ofloxacin compared with gentamicin in the treatment of external ocular infection. Ofloxacin Study Group.
Gwon A
Br J Ophthalmol; 1992 Dec; 76(12):714-8. PubMed ID: 1486071
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.
Zhang YY; Huang HH; Ren ZY; Zheng HG; Yu YS; Lü XJ; Xiao ZK; Yang HF; Xiu QY; Chen BY; Yue HM; Hao QL; Huang JA; Ma H; Xiao W; Guo DY; Si B; Sun SH; Zhang W; Li QH; Shen HH; Duan J; Li HY; Yao WZ; Gu JM; Xia QM; Ying KJ; Liu A; Yang HP; Shi MH; Sun TY; Ding GH; Wu GM
J Infect Chemother; 2009 Oct; 15(5):301-11. PubMed ID: 19856068
[TBL] [Abstract][Full Text] [Related]
16. Bacteriologic and clinical efficacy of ofloxacin 0.3% versus ciprofloxacin 0.3% ophthalmic solutions in the treatment of patients with culture-positive bacterial keratitis.
Prajna NV; George C; Selvaraj S; Lu KL; McDonnell PJ; Srinivasan M
Cornea; 2001 Mar; 20(2):175-8. PubMed ID: 11248824
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
18. Eye drops and eye gels of levofloxacin: comparison of ocular absorption characterizations and therapeutic effects in the treatment of bacterial keratitis in rabbits.
Li G; Xu L; Jiang M; Wu X
Drug Dev Ind Pharm; 2020 Apr; 46(4):673-681. PubMed ID: 32233932
[TBL] [Abstract][Full Text] [Related]
19. Ocular penetration of levofloxacin, ofloxacin and ciprofloxacin in eyes with functioning filtering blebs: investigator masked, randomised clinical trial.
Cantor LB; WuDunn D; Yung CW; Valluri S; Catoira YP; Hoop JS; Morgan LS
Br J Ophthalmol; 2008 Mar; 92(3):345-7. PubMed ID: 18211932
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.
Ohno S; Umebayashi I; Matsukawa M; Goto T; Yano T
Arthritis Res Ther; 2019 Jan; 21(1):2. PubMed ID: 30611312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
